Health Utilities Associated with Pneumococcal Diseases in Children and Adults: A Targeted Literature Review and Meta-analysis [0.03%]
Min Huang,Hela Romdhani,Yan Song et al.
Min Huang et al.
Background: Pneumococcal disease and post-meningitis sequelae (PMS) impact health-related quality of life (HRQoL). However, health utility estimates for these conditions vary considerably in the literature, which may affe...
Correction: Incremental Disease Burden (Healthcare Costs and Resources) of Duchenne Muscular Dystrophy in the US: A Matched Cohort Analysis [0.03%]
Mena Scavina,Nate Posner,Patricia Dorling et al.
Mena Scavina et al.
Published Erratum
PharmacoEconomics - open. 2026 Mar 31. DOI:10.1007/s41669-026-00646-x 2026
Prevalence and Healthcare Costs of Metabolic Disorders Among Individuals with Schizophrenia Following Initiation of Oral Antipsychotic Therapy [0.03%]
Joseph Tkacz,Alejandro Cajigal,Matthew Sidovar et al.
Joseph Tkacz et al.
Background/objective: Metabolic disorders are prevalent among the schizophrenia population due to relatively poor access to healthcare, lifestyle factors, genetics, and metabolic side effects associated with antipsychotic...
Cost-Effectiveness of Follitropin Delta Compared with Follitropins Alfa and Beta in Controlled Ovarian Stimulation for Assisted Reproductive Technologies (ART) in France [0.03%]
法国辅助生殖技术控制卵巢刺激中 Follicrin delta 与 Follicrin alpha 和 beta 的成本效益比较
Samir Hamamah,Jeremy Carette,Henri Leleu et al.
Samir Hamamah et al.
Background: Follitropin delta, using a personalized dosing regimen, is an effective treatment option for women undergoing controlled ovarian stimulation (COS) for in vitro fertilization (IVF)/intracytoplasmic sperm inject...
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned? [0.03%]
西班牙中重度克罗恩病序贯治疗策略的成本效益分析：生物类似物乌司奴单抗应处于什么位置？
Iago Rodríguez-Lago,José Ignacio Peinado-Fabregat,Marcelo Guigini et al.
Iago Rodríguez-Lago et al.
Background/objective: Crohn's disease is associated with a high economic burden for the Spanish National Healthcare System, driven by pharmacological expenses. Following the recent incorporation of ustekinumab biosimilars...
Cost-Utility Analysis of Faricimab Versus Aflibercept in Treating Neovascular Age-Related Macular Degeneration (nAMD) in the United States [0.03%]
关于在美国治疗湿性年龄相关性黄斑变性(FAΜD)的Faricimab与Aflibercept成本效用分析
Ahmead Baljoon,Vakaramoko Diaby,Sandra Suther et al.
Ahmead Baljoon et al.
Background/objective: Neovascular age-related macular degeneration (nAMD) imposes a substantial clinical and economic burden in the United States (US). Faricimab offers the potential for longer dosing intervals than aflib...
Cost Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Older Adults in Portugal [0.03%]
葡萄牙老年人带状疱疹佐剂重组亚单位疫苗的成本效益分析
Eleftherios Zarkadoulas,Fábio Silva,Joana Alves et al.
Eleftherios Zarkadoulas et al.
Background and objectives: Herpes zoster (HZ) and associated complications comprise a considerable public health burden in older adults. This study aimed to evaluate the cost-effectiveness of recombinant zoster vaccine (R...
Valuing Maintenance of Visual Function in Retinitis Pigmentosa: A Discrete Choice Experiment with Patients and the General Public [0.03%]
视网膜色素变性患者的视觉功能维持医疗价值定量研究：一种离散选择实验方法
Kevin Marsh,Myrto Trapali,Mike Ingham et al.
Kevin Marsh et al.
Background and objectives: Retinitis pigmentosa (RP) is a progressive and sight-threatening condition with few treatment options. Patients with RP experience variable progressive vision deterioration that can severely aff...
Understanding the Humanistic Burden of Metabolic Dysfunction-Associated Steatohepatitis Liver Disease in the US Population: Age/Sex Stratified Analysis of Morbidity and Mortality [0.03%]
美国代谢紊乱相关非酒精性脂肪肝病的人文负担——基于年龄/性别分层的疾病和死亡分析
Andrew H Briggs,Ziyi Lin,Daniel Aggio et al.
Andrew H Briggs et al.
Background and aims: Metabolic dysfunction-associated steatohepatitis (MASH) is defined by a buildup of fat in the liver and signs of inflammation and liver damage (fibrosis). Eventually, subjects with MASH may develop ci...
Comparative Cost-Effectiveness Analysis of Multiple First-Line Treatments for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer in Japan [0.03%]
日本HER2阴性不可切除晚期或复发胃癌一线治疗的多种疗法成本效益分析比较研究
Kosuke Morimoto,Kensuke Moriwaki,Yoshitaka Nishikawa et al.
Kosuke Morimoto et al.
Background/objective: HER2-negative unresectable advanced or recurrent gastric cancer (GC) has a poor prognosis. This study evaluated the comparative cost-effectiveness of multiple first-line treatment options from the Ja...